Enlivex Therapeutics Ltd. — FY2019 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2019. This is an annual report; it does not provide a clear standalone fourth-quarter income statement. Financial figures below are U.S. dollars unless noted, generally in millions.
Business context
Enlivex is an Israeli clinical-stage immunotherapy company developing Allocetra, an allogeneic cell therapy intended to rebalance immune responses. Its lead focus shifted toward sepsis after encouraging Phase Ib results; development for graft-versus-host disease (GvHD) was deferred. The March 2019 merger with Bioblast was accounted for as a reverse recapitalization, with Enlivex R&D treated as the accounting acquirer and historical predecessor.
Financial performance and position
| Metric | FY2019 / Dec. 31, 2019 | FY2018 / Dec. 31, 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense, net | $5.724 | $4.255 |
| General and administrative expense | $2.895 | $1.044 |
| Operating loss | $(8.619) | $(5.299) |
| Net loss | $(9.384) | $(4.242) |
| Basic and diluted loss per share | $(1.11) | $(1.40) |
| Net cash used in operating activities | $(7.041) | $(3.161) |
| Cash and cash equivalents | $3.948 | $9.736 |
| Short-term deposits | $8.060 | $0.040 |
| Current assets / current liabilities | $16.421 / $5.980 | $10.277 / $1.130 |
| Total assets / total liabilities | $17.560 / $6.278 | $11.034 / $1.328 |
Working capital was approximately $10.4 million. The balance sheet reports no conventional borrowings; liabilities included $3.4 million payable to contingent value right (CVR) holders. The filing does not report meaningful operating margins because the company had no revenue.
Changes versus prior year
- R&D expense rose 34% to $5.724 million, reflecting higher personnel, clinical and preclinical activity, partly offset by $1.082 million of Israel Innovation Authority (IIA) grant participation.
- G&A expense increased 177% to $2.895 million, including higher professional fees, director compensation, insurance and payroll.
- Net loss more than doubled to $9.384 million. Net financial expense was $0.765 million, versus net financial income of $1.057 million in 2018; foreign-exchange effects were a significant factor.
- Operating cash use increased to $7.041 million. Investing cash use was $6.359 million, mainly reflecting short-term deposits and facility-related spending; financing provided $8.306 million, including merger-related private-placement proceeds and option exercises.
Outlook, risks and unusual items
- Management expected, after post-year-end financing, to fund planned operations through the fourth quarter of 2022. It also warned that continued development requires substantial additional funding and that absent adequate financing there was substantial doubt about continuing activities beyond that period.
- In February and March 2020, the company completed registered direct offerings with aggregate gross proceeds of $24.75 million. The March offering included investor warrants, creating potential dilution.
- In late 2019, Enlivex completed a Phase Ib sepsis study involving 10 treated patients. A subsequent analysis reported no deaths among treated patients versus 27% mortality among 37 historical matched controls, and average ICU stays of 4 versus 11.11 days. These are small-study, nonrandomized comparisons, not evidence of confirmed efficacy; the company reported no serious unexpected severe adverse reactions or serious adverse events.
- Management planned, subject to regulatory approval, to start a Phase IIb or Phase II/III sepsis study during 2020, targeting up to 100 patients. Matched-donor-cell GvHD trials were rescheduled to 2022, pending results in sepsis and related indications.
- Trehalose-related assets were sold to Seelos in 2019. The balance sheet included a $2.0 million receivable and $1.5 million cash held under the CVR arrangement; the company also recorded $3.4 million payable to CVR holders. Further milestone payments of up to $17 million and royalties were contingent on specified development and regulatory events.
- IIA-supported programs carry contingent royalties generally of 3%–5% of relevant sales until grants plus interest are repaid. The disclosed contingent obligation was approximately $5.197 million; IIA approval and potential additional payments may apply to certain transfers or overseas manufacturing/licensing.
- Key risks include no approved products or product revenue, recurring losses and financing dependence, clinical and regulatory uncertainty, complex cell manufacturing and blood-supply risks, competition, foreign-exchange exposure, and potential operational disruption from COVID-19. The auditor reported effective internal control over financial reporting at year-end; a material weakness identified for 2018 was reported as remediated.
Important facts for investors to verify
- Cash availability and actual runway after offering costs, planned trial spending and any restrictions on CVR-related cash; also assess dilution from outstanding and newly issued warrants.
- Whether the sepsis results can be replicated in a randomized, controlled trial, and the trial’s regulatory status, design, enrollment and funding.
- Collection and distribution of the Trehalose proceeds and CVR obligations, including the terms and likelihood of contingent milestone payments.
- IIA royalty and approval obligations, including potential effects on licensing, technology transfers and manufacturing outside Israel.
- The filing’s audited financial statements and notes for the merger accounting, share-based compensation, related-party arrangements and subsequent financing details.